Advancing Together: Asieris and UroViu Strengthen Partnership for Enhanced Bladder Cancer Diagnosis and Treatment

Asieris Pharmaceuticals, a global biopharmaceutical company dedicated to pioneering innovative treatments for genitourinary tumors and related diseases, has recently announced an exciting development in its partnership with UroViu Corporation (“UroViu”). This strategic collaboration grants Asieris exclusive global rights to utilize UroViu’s patented portable single-use cystoscope technology in the domain of fluorescent imaging. This advancement marks a significant step forward in the quest to enhance the diagnosis and postoperative monitoring of Non-Muscle Invasive Bladder Cancer (NMBC) through cutting-edge non-white light imaging techniques. Asieris Pharmaceuticals will not only spearhead the research efforts in this area but will also take charge of the worldwide commercialization of the sterile single-use fluorescent Cystoscope.